Trials / Completed
CompletedNCT06231550
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.
Detailed description
FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FC084CSA tablets | FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-03-18
- Completion
- 2025-03-18
- First posted
- 2024-01-30
- Last updated
- 2025-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06231550. Inclusion in this directory is not an endorsement.